API
< Back to all clusters
[HEALTH] · Brazil, India · 28 sources

started · updated

Anvisa approves five new injectable pens for diabetes and obesity

Brazil’s National Health Surveillance Agency (Anvisa) has approved the registration of five new injectable medications for the treatment of type 2 diabetes and obesity. The products, which will be sold as applicator pens, utilize semaglutide or liraglutide. These substances act as GLP-1 receptor agonists, mimicking a hormone that signals satiety to the brain and aids in glycemic control and weight loss.

The medications are manufactured by Indian laboratories Biocon and OneSource Specialty. In Brazil, the registrations were granted to three companies: Farma Vision Importação e Exportação de Medicamentos, Aché Laboratórios Farmacêuticos, and Dr. Reddy’s Farmacêutica do Brasil.

For diabetes treatment, the approved products include Aribet (liraglutide), Embeltah (semaglutide), and Sevema (semaglutide). For obesity treatment, intended to be used alongside diet and exercise, Anvisa authorized Lyrza (liraglutide) and Wylovol (liraglutide). With these new approvals, Anvisa has authorized a total of 20 GLP-1 pens in 2026.

Entities

Aché Laboratórios Farmacêuticos · Anvisa · Biocon · Dr. Reddys Farmacêutica do Brasil · Dr. Reddy’s Farmacêutica do Brasil · Dr. Reddy’s Laboratories · OneSource Specialty

Claims

What the coverage asserts, and how many sources carry each claim.

Sources